ASCO 2020：11项中国研究入选口头简报，17项Poster简报

颇受全球新冠禽流感阻碍，原定于5月末29日~6月末2日在芝加哥举行的英美两国流行病学学会（ASCO）讨论会今年将首次以该线上型式开幕，这是现有最大规模的该线上盛会。今天，内阁会议的内容可试题列入，共103个sessions，近现代共有11项研究者入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

巯基替尼或托雷斯替尼加卡培他浜可用HER2+移出性乳腺腹腔癌（PHOEBE）：一项III期随机检验。

音乐会：移出性乳腺腹腔癌

编者：近现代医科大学病房徐兵河大学教授、马飞大学教授，北京师范大学附属机构病房胡夕春大学教授等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三有性乳腺腹腔癌标准病人后卡培他浜可维持节拍化疗的III期检验（SYSUCC-001）。

音乐会：乳腺腹腔癌—发散/区域/来进行病人

编者：里面文系防治该里面心中山王树森大学教授等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

借助移出性脑的性状特征来计算脑脊液里面可逆DNA检验的期望值: 新方法对抗外公取胜

音乐会：新方法解决外公问题

编者：郭美芹 郭皮克等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

塔纳非尼对里拉拉非尼作为里面叶肝巨噬细胞腹腔癌的前沿病人：一项免费标识、随机、多该里面心II/III期检验。

音乐会：腹腔肠道腹腔癌—腹腔冠状动脉、胰脏和水火

编者：四川大学华西病房毕锋大学教授、近现代民主自由解放军八一病房秦叔逵大学教授等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

近现代里面叶肝腹腔癌病症阿帕替尼西段病人：一项随机、安慰剂对照、安慰剂III期研究者

音乐会：腹腔肠道腹腔癌—腹腔冠状动脉、胰脏和水火

编者：近现代民主自由解放军八一病房秦叔逵大学教授、四川大学华西病房郭秋大学教授等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

里面叶继发卵巢腹腔癌二次巨噬细胞减灭术的一项随机III期检验：SOC1 / SGOG-OV2。

讲座：妇科腹腔癌症

编者：北京师范大学附属机构永康病房臧荣余大学教授等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈腹腔癌根治性卵巢切除术后来进行病人里面的序贯放化疗对比直接恶性肿瘤或不间断放化疗（STARS研究者）：一项随机、对照、免费标识的III期检验。

内阁会议：妇科腹腔癌症

编者：里面文系防治该里面心黄鹤大学教授、刘继红大学教授等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：来进行吉非替尼对比化疗可用可切除的EGFR突变的N1-N2期NSCLC-随机III期流行病学检验的最终总体求生存比对。

讲座：肝腹腔癌—非小巨噬细胞发散-区域/小巨噬细胞/其他腿部

编者：广东省民主自由病房吴一龙大学教授等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变辄移出非小巨噬细胞肝腹腔癌病症前沿酪氨酸蛋白激酶抑制剂合组或不合组积极前该线发散恶性肿瘤：III期免费标识流行病学随机检验（SINDAS）的里面期结果（NCT02893332）。

讲座：肝腹腔癌-非小巨噬细胞移出

编者：重庆市民主自由病房曾铭大学教授等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对比如说死亡-1（PD-1）的人源化IgG4单克隆抗体合组阿昔替尼可用移出性黏膜黑色素结节病症的Ib期研究者的总求生存期和海洋生物多种类型比对。

讲座：黑色素结节/皮肤腹腔癌

编者：北京大学病房郭军、盛锡楠大学教授等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可用性和结果：共通CAR-T巨噬细胞首次化学物质检验病人入院/难治性T巨噬细胞急性淋巴巨噬细胞癌症（r/r T-ALL）的可用性和。内阁会议：开发里面的病人技术-免疫病人。编者：郭明欣等内容可：3013宣传品：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利他汀在里面叶冠状动脉楔形巨噬细胞腹腔癌病症里面的应用领域：一项随机的免费标识II期检验（ORIENT-2）。内阁会议：腹腔肠道腹腔癌-腹腔冠状动脉腹腔癌、胰脏腹腔癌和水火道腹腔癌编者：徐建明大学教授等内容可：4511宣传品：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T巨噬细胞对滋养母巨噬细胞结节的根除性病人内阁会议：骨骼肌编者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、杨旭东内容可：2522宣传品。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在里面叶错配修复缺陷病症里面的应用领域内阁会议：开发里面的病人学-免疫病人编者：沈琳大学教授等内容可：3021宣传品。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 诱导CD7-CART病人入院/难治性ACUTE淋巴巨噬细胞癌症/淋巴结节的首例化学物质流行病学检验内阁会议: 开发性病人学-免疫病人编者简介：张明志，杨林等内容可：3026宣传品: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）合组应可用里面叶也就是说结节病症的Ib期研究者内阁会议：发展性病人学--分子会核酸药物和海洋生物学编者：龚继芳，沈琳大学教授等内容可：3523宣传品：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合组嘌呤和nedaplatin病人继发或移出性冠状动脉楔形巨噬细胞腹腔癌（ESCC）病症的II期研究者。内阁会议：腹腔肠道腹腔癌-腹腔冠状动脉、胰脏和水火道腹腔癌的研究者编者：中山王志强，郭玉红，中山王德申，中山王凤华，任超，谭琼 中山王志强、郭玉红、中山王德深、中山王凤华、任超、谭琼内容可：4522宣传品：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.内阁会议：腹腔肠道腹腔癌-腹腔冠状动脉腹腔癌、胰脏腹腔癌和水火管腹腔癌的西段病人编者：宋艳等内容可：4524宣传品：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环RNA分类器可用初始活检时检验高等级腹腔癌的尿液外体环RNA分类器：一项多该里面心的回顾性研究者内阁会议：泌尿生殖系统腹腔癌症；还有腹腔癌、睾丸腹腔癌和腹腔癌编者简介：Liaoyuan Li等内容可：5522宣传品。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 发散里面叶宫颈腹腔癌并发化疗后的来进行化疗内阁会议: 妇科腹腔癌症编者简介： 郭珉珉等内容可：6031宣传品：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病人甲状腺滋养性腹腔癌的相关性：基于ALTER01031检验的比对。会话：躯干编者：天津市病房用心大学教授内容可：6526宣传品。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、个数和年龄组对安洛替尼病人后病症结局的阻碍: ALTER01031的亚组比对内阁会议：躯干编者：天津市病房用心大学教授内容可：6527宣传品。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA比对计算I-IIIA期非小巨噬细胞肝腹腔癌（NSCLC）病症术后入院: GASTO1035和GASTO1018的结果内阁会议：肝腹腔癌-非小巨噬细胞发散-区域性/小巨噬细胞/小巨噬细胞/其他胸科腹腔癌症编者：Si-Yu Wang等内容可：9023宣传品：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小巨噬细胞肝腹腔癌（NSCLC）里面EGFR酪氨酸蛋白激酶抑制剂的新型脑膜炎程序内阁会议:肝腹腔癌-非小巨噬细胞移出性肝腹腔癌编者简介：杨昕，金结缘，满宇，欧真假，宝珠，薛武，杨少，范敏 杨昕、金结缘、满宇、欧真假、宝珠、薛武、杨绍、范敏内容可：9528宣传品：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1检验里面里面叶黑色素结节总求生存的替代终点内阁会议：黑色素结节/皮肤腹腔癌编者：聂润聪，袁书强，郭元芳，陈英波，周志伟 聂润聪、袁书强、郭元芳、陈英波、周志伟内容可：10030宣传品：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病人入院或移出性高血压恶性骨病症的II期研究者内阁会议： 肉结节编者：唐丽娜，牛晓辉，陈赓，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、汪直、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525宣传品。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步赞扬安罗替尼在里面叶肉结节病症多该线病人里面的可用性和。内阁会议：肉结节编者：姚伟涛，中山王家强，浙江余姚人，郭明，杜新辉，田志浩，牛晓颖 姚伟涛、中山王家强、浙江余姚人、中山王鑫、杜鑫辉、田志超、牛晓英内容可：11526宣传品：414